| Gregory Warner Dursteler, DO | |
|
100 Hillcrest Medical Blvd, Waco, TX 76712-8897 | |
| (254) 202-5300 | |
| Not Available |
| Full Name | Gregory Warner Dursteler |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 8 Years |
| Location | 100 Hillcrest Medical Blvd, Waco, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124473848 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R9944 (Texas) | Secondary |
| 208M00000X | Hospitalist | R9944 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Medical Center Hillcrest | Waco, TX | Hospital |
| Baylor Scott & White Pavilion - Temple | Temple, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hillcrest Physician Services | 1153304456 | 90 |
News Archive
Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.
People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.
NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.
National Health Investors, Inc. announced today it has closed on a $100 million unsecured revolving credit facility to fund new healthcare real estate investments. The new credit facility, which was provided by Regions Bank as agent and Pinnacle National Bank as a participating bank, bears interest at a margin of 250 basis points over LIBOR with a floor of 1% and matures in February 2011.
› Verified 3 days ago
| Entity Name | Hillcrest Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649294323 PECOS PAC ID: 1153304456 Enrollment ID: O20040609000104 |
News Archive
Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.
People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.
NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.
National Health Investors, Inc. announced today it has closed on a $100 million unsecured revolving credit facility to fund new healthcare real estate investments. The new credit facility, which was provided by Regions Bank as agent and Pinnacle National Bank as a participating bank, bears interest at a margin of 250 basis points over LIBOR with a floor of 1% and matures in February 2011.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory Warner Dursteler, DO Po Box 848491, Dallas, TX 75284-8491 Ph: () - | Gregory Warner Dursteler, DO 100 Hillcrest Medical Blvd, Waco, TX 76712-8897 Ph: (254) 202-5300 |
News Archive
Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.
People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.
NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.
National Health Investors, Inc. announced today it has closed on a $100 million unsecured revolving credit facility to fund new healthcare real estate investments. The new credit facility, which was provided by Regions Bank as agent and Pinnacle National Bank as a participating bank, bears interest at a margin of 250 basis points over LIBOR with a floor of 1% and matures in February 2011.
› Verified 3 days ago
Joy R Burrell, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1600 Providence Dr, Waco, TX 76707 Phone: 254-313-4200 Fax: 254-313-4531 | |
Dr. Alcario Serros Iii, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 100 Hillcrest Medical Blvd, Waco, TX 76712 Phone: 254-202-2000 Fax: 254-202-5651 | |
Alyssa Munkres Deaton, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 100 Hillcrest Medical Blvd, Waco, TX 76712 Phone: 254-202-2000 | |
Biresh Kumar, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5940 Crosslake Pkwy, Waco, TX 76712 Phone: 254-666-2999 Fax: 254-666-6000 | |
Dr. Floyd Lee Barry, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1911 Martin Luther King Blvd, Waco, TX 76704 Phone: 254-313-5000 Fax: 254-313-4531 | |
Richa Sharma, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 100 Hillcrest Medical Blvd, Waco, TX 76712 Phone: 254-202-2000 Fax: 254-202-5651 | |
Michelle R Felan-palmer, AGACNP-BC Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 100 Hillcrest Medical Blvd, Waco, TX 76712 Phone: 254-202-2000 |